Blinklab Limited

BB1.ASX

Health Care

Market Data

Price

$0.670

-0.0%
Market Cap

$107.3M

P/E Ratio

-100000.0x

EPS

$-0.062

Div. Yield

0.00%

52-Week Change

-0.1%

Latest Earnings

2026 Annual Report & Appendix 4E

31 July 2026

Revenue
$1.21
+222.0% YoY
NPAT
-$7.22
-26.5% YoY
EPS
$-0.06

BlinkLab reported FY2026 revenue of $1.21M (up 222% YoY) but incurred a net loss of $7.22M (27% worse than prior year), reflecting significant investment in R&D and commercialization of its AI-powered digital diagnostics platform. The company achieved critical clinical milestones including successful U.S. pilot study results (83.7% sensitivity/84.7% specificity for autism) and peer-reviewed publication, positioning it for FDA 510(k) pivotal study progression, with $17.95M in cash providing runway for operations. Key points: Revenue growth of 222% YoY to $1.21M demonstrating early commercial traction; U.S. pilot study successfully enrolled 485 children with 83.7% sensitivity and 84.7% specificity for autism diagnosis, exceeding FDA target thresholds of >65%; Core technology published in Autism Research, a leading peer-reviewed journal, providing independent scientific validation

Recent Announcements

31 Jul 2026 Actual Results Positive

2026 Annual Report & Appendix 4E

BlinkLab reported FY2026 revenue of $1.21M (up 222% YoY) but incurred a net loss of $7.22M (27% worse than prior year), reflecting significant investment in R&D and commercialization of its AI-powered digital diagnostics platform. The company achieved critical clinical milestones including successful U.S. pilot study results (83.7% sensitivity/84.7% specificity for autism) and peer-reviewed publication, positioning it for FDA 510(k) pivotal study progression, with $17.95M in cash providing runway for operations. Key points: Revenue growth of 222% YoY to $1.21M demonstrating early commercial traction; U.S. pilot study successfully enrolled 485 children with 83.7% sensitivity and 84.7% specificity for autism diagnosis, exceeding FDA target thresholds of >65%; Core technology published in Autism Research, a leading peer-reviewed journal, providing independent scientific validation

Get real-time alerts for BB1

Receive AI-powered earnings summaries and instant notifications when Blinklab Limited releases results.

Register Free